

# Do maternal fibroids play a role in NIPS?

Tarrash, M<sup>1</sup>, Rabin-Havt S<sup>2</sup>, Gao, Q<sup>3</sup>, Klugman S<sup>2</sup>

1. Department of Obstetrics and Gynecology, Northwell Health at Long Island Jewish Medical Center and North Shore University Hospitals, Queens, USA  
2. Department of Obstetrics & Gynecology and Women's Health, Division of Reproductive and Medical Genetics, Albert Einstein College of Medicine / Montefiore Medical Center  
3. Department of Epidemiology & Population Health, Albert Einstein College of Medicine

## INTRODUCTION

- Noninvasive prenatal screening (NIPS) evaluates cell-free fetal DNA (cfDNA) from the maternal circulation<sup>1</sup>
- NIPS has a high sensitivity and specificity for trisomy 21, trisomy 18, trisomy 13, and sex chromosome aneuploidies<sup>1</sup>
- Discrepancies between fetal karyotype and NIPS results can be caused by a vanishing twin, demise of a twin, low fetal fraction, maternal chromosome abnormality and maternal disease<sup>2,3</sup>.
- It is estimated that the prevalence of fibroids, benign uterine tumors, varies by ethnicity and affects 1:10.4 people<sup>4</sup>
- Previous studies have attributed high risk NIPS results to maternal fibroids<sup>5,6</sup>

## AIM

- Assess whether the presence of maternal fibroids has an influence on high risk noninvasive prenatal screening (NIPS) results

## METHODS

- A retrospective cohort study was conducted to compare the accuracy of the NIPS results to the presence of maternal fibroids
- Inclusion criteria were singleton pregnancies with high risk NIPS results, and accessible pregnancy outcome information
- 11,880 prenatal patients received NIPS during the study period. 171 were identified as high risk via NIPS
- Total fibroid volume was calculated based on early gestational age sonograms
- NIPS results were then compared to diagnostic testing results, ultrasound findings, or postnatal diagnostic testing and physical exam




Figure 1: NIPS (noninvasive prenatal screening) study design

Characteristics	Concordant NIPS N = 89	Discordant NIPS N = 49	Total	p-value
Presence of fibroid n, (%)	8 (9.0%)	7 (14.3%)	15 (10.9%)	0.339
Total fibroid volume mean (SD)	8.3 (46.5)	25.7 (116.6)	14.4 (78.9)	0.216
GD/Diabetes	9 (10.1%)	8 (16.3%)	17 (12.3%)	0.288
HTN/pre-eclampsia	13 (14.6%)	8 (16.3%)	21 (15.2%)	0.788
Consanguinity	2 (2.2%)	1 (2.0%)	3 (2.2%)	1

Table 1: Medical history of women with concordant NIPS compared to women with discordant NIPS

## RESULTS

- Between March 2014 and August 2019, 11,880 prenatal patients had NIPS during prenatal care at Montefiore Medical Center. Of those, 171 patients had high risk results and 138 were eligible for the study
- A total of 35.5% (49/138) of all high risk NIPS results were discordant and those patients ultimately had chromosomally normal babies.
- The mean total fibroid volume in the concordant NIPS group was 8.3 cm<sup>3</sup> versus 25.7cm<sup>3</sup> total fibroid volume in the discordant NIPS group (p = 0.216)
- The odds of a discordant NIPS result among patients with fibroids was 3.486 (95% CI: 0.846, 14.354) times those without fibroids, adjusting for fetal fraction, maternal age, gestational age, BMI and race

## CONCLUSIONS

- Although not statistically significant, women with fibroids have a higher chance of receiving discordant NIPS results
- Additional studies are necessary to determine the relationship of presence and size of fibroids on the accuracy of NIPS results

## REFERENCES

1. A, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med.* 2016;18(10):1056–65.
2. Grati FR, Malvestiti F, Ferreira JC, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. *Genet Med.* 2014;16(8):620–624. doi:10.1038/gim.2014.3
3. Futch T, Spinoso J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. *Prenat Diagn* 2013;33:569–74.
4. Yu, O., Scholes, D., Schulze-Rath, R., Grafton, J., Hansen, K., & Reed, S. D. (2018). A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014. *American Journal of Obstetrics and Gynecology*, 219(6), 591-e1.
5. Dharajiya, N. G., Namba, A., Horiuchi, I., Miyai, S., Farkas, D. H., Almasri, E., ... & Kamei, Y. (2015). Uterine leiomyoma confounding a noninvasive prenatal test result. *Prenatal diagnosis*, 35(10), 990-993.
6. McCullough, Ron M., et al. "Non-invasive prenatal chromosomal aneuploidy testing-clinical experience: 100,000 clinical samples." *PLoS one* 9.10 (2014): e109173.